HeartBeam Inc. management will participate in several investor and industry conferences throughout March 2026, presenting the company's FDA-cleared cardiac monitoring technology to financial and medical audiences. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also conducting meetings with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel discussion focused on technologies that advance healthy aging. This participation underscores the broader application of HeartBeam's technology in preventive and long-term cardiac care management.
Subsequently, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference, from March 28-30. At this premier cardiology event, the company plans to showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. The company's latest news and updates are available in its newsroom at https://ibn.fm/BEAT.
HeartBeam's core technology represents a significant advancement in cardiac care. The company is developing the first cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from non-coplanar directions and synthesizing them into a standard 12-lead ECG. This platform is designed for portable use outside medical facilities, allowing physicians to monitor cardiac health trends and identify acute conditions remotely, thereby directing patients to appropriate care. The technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. Details on the intended use of the technology are available at https://www.heartbeam.com/indications. The company holds over 20 issued patents supporting this technological approach.
The series of conference appearances highlights HeartBeam's transition from a development-stage company to one commercializing a cleared medical device. Engaging with investors at the Oppenheimer and ROTH conferences is crucial for securing capital and building market confidence, while presence at ACC.26 is vital for driving clinical adoption and forming strategic partnerships within the medical community. The company's focus on enabling actionable heart intelligence outside traditional healthcare settings positions it at the forefront of a shift toward decentralized and remote patient monitoring in cardiology. This strategic outreach during March 2026 is therefore critical for establishing the technology's market presence, securing necessary financial backing, and integrating its innovative monitoring solutions into standard cardiology practice, which could significantly improve patient access to continuous cardiac assessment and early intervention.
